Recruiting
Phase 3

Daraxonrasib

Sponsor:

Revolution Medicines, Inc.

Code:

NCT06881784

Conditions

NSCLC (Non-small Cell Lung Cancer)

Non-Small Cell Lung Cancer

NSCLC

NSCLC (Non-small Cell Lung Carcinoma)

NSCLC (Advanced Non-small Cell Lung Cancer)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

daraxonrasib

docetaxel

Study Details

Brief summary:

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Conditions

NSCLC (Non-small Cell Lung Cancer)

Non-Small Cell Lung Cancer

NSCLC

NSCLC (Non-small Cell Lung Carcinoma)

NSCLC (Advanced Non-small Cell Lung Cancer)

Study ID

NCT06881784

Start date

May 6, 2025

Status verified date

Jul, 2026

Completion date

Dec 1, 2030

Anticipated

Primary completion date

Dec 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.
  • Measurable disease per RECIST v1.1.
  • Adequate organ function (bone marrow, liver, kidney, coagulation).
  • One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.
  • Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).
  • Able to take oral medications.

Exclusion Criteria:

  • Prior therapy with direct RAS-targeted therapy or docetaxel.
  • Untreated central nervous system (CNS) metastases.
  • Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).
  • Ongoing anticancer therapy.
  • Pregnant or breastfeeding.

Study Design

Enrollment

590 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: daraxonrasib

study drug

active comparator: docetaxel

Patients randomized to the comparator control arm will receive docetaxel as the standard of care therapy.

Interventions

daraxonrasib

oral tablets

docetaxel

intravenous (IV) infusion

Primary outcome measure

  • Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) [ Time Frame: Up to approximately 4 years ]
  • Overall survival (OS) in the RAS G12X-C population [ Time Frame: Up to approximately 4 years ]

Central Contacts and Locations

Central contacts

Revolution Medicines Study Director

1-844-2-REVMEDmedinfo@revmed.com

Locations

UC Irvine Health

Recruiting

Orange, California, United States, 92868

More Information

Sponsor

Revolution Medicines, Inc.

Last update posted

Nov 6, 2026

Last verified

Jul, 2026

Keywords

  • NSCLC
  • Non-Small Cell Lung Cancer
  • Lung Cancer
  • RAS
  • KRAS
  • HRAS
  • NRAS
  • RAS Q61 Mutation
  • RAS G12 Mutation
  • RAS G13 Mutation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Revolution Medicines, Inc. on 2026-11-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.